MANILA, Philippines — The camp of Department of Public Works and Highways (DPWH) District Engineer Henry Alcantara denied accusations linking him to alleged ghost flood control projects in Bulacan, insisting he had no hand in the supposed scheme.
In a statement issued over the weekend, the Flaminiano Arroyo & Dueñas law firm, which represents Alcantara, said its client “maintains his innocence: he did not author these alleged ghost projects. Any wrongdoing was done behind his back, without his knowledge, acquiescence, or approval.”
DPWH engineer denies role in Bulacan flood control ‘ghost projects’
The statement directly counters claims that Alcantara was the “kingpin” of the controversial projects, which authorities are now investigating for possible irregularities., This news data comes from:http://vt-atd-mcww-kvs.ycyzqzxyh.com
“Engr. Alcantara will contest every accusation that he had supposedly participated in and/or benefitted from any unlawful scheme,” the law firm said, adding that he would exhaust all legal remedies, including challenging his summary dismissal from service.

The camp also vowed Alcantara’s cooperation with the ongoing investigation. “He will continue to assist the authorities in the investigation of these flood control ghost projects. We are confident that in due time, the truth will surface and Engr. Alcantara will be cleared of the baseless accusations levied against him,” the statement read.
- Israel expects 1 million Gazans to flee new offensive
- AI, thinner iPhones likely stars of Apple 'Awe Dropping' event
- Indonesia's delayed new capital risks 'white elephant' status
- Workers urge Marcos to stop corruption by banning political dynasties
- Former Bulacan district engineer admits going to casinos
- Thai woman jailed for 43 years for lese majeste freed
- Comelec defers reconstitution of BARMM parliamentary districts
- Corruption crackdown: VP Sara Duterte, lawmakers call for deeper probe into government
- Israeli PM tells Gaza City residents to 'leave now'
- Trump plans a hefty tax on imported drugs, risking higher prices and shortages